Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Potassium sodium hydrogen citrate** is a defined mixed potassium-sodium hydrogen citrate salt, typically specified as potassium sodium hydrogen citrate (6:6:3:5), used as an oral urinary alkalinizer and citrate replacement agent. It is marketed as **Uralyt-U** granules for oral solution. After oral administration, it raises urinary pH and citrate excretion; alkalinization increases the solubility of uric acid and cystine, while citrate complexation and reduced urinary free calcium lower supersaturation of calcium-containing stone salts. It is used for dissolution and recurrence prevention of uric acid stones and, in certain marketed product labels, metaphylaxis of calcium-containing urinary stones. ([viatris.com.cn](https://viatris.com.cn/-/media/project/viatris-sites/product-document/09uralyt.pdf))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on potassium sodium hydrogen citrate.